[Chronic lesion of the interlobular bile ducts induced by fenofibrate].
We report a case of chronic intra-hepatic cholestasis observed after 5 months treatment of fenofibrate, a drug extensively prescribed in the treatment of dyslipidemia. Clinically asymptomatic liver injury was revealed by a marked elevation of GGT activity, associated with a moderate increase in alkaline phosphatase and aminotransferases activities. GGT activity remained moderately increased 2 years after discontinuation of treatment. Examination of a liver biopsy showed a reduction in the number of interlobular bile ducts. This case emphasizes the need for systematic and repeated control of blood liver tests in patients receiving fenofibrate therapy.
Lepicard
A
A
Service d'Hépatologie et de Gastroentérologie, Hôpital Henri-Mondor, Créteil.
Mallat
A
A
Zafrani
E S
ES
Dhumeaux
D
D
D002780:Cholestasis, Intrahepatic / Q000097:blood / Q000139:chemically induced*; D002908:Chronic Disease; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008111:Liver Function Tests; D008875:Middle Aged
D011345:Fenofibrate